ProfileGDS5678 / 1418016_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 89% 90% 90% 90% 90% 90% 91% 89% 89% 90% 90% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9090689
GSM967853U87-EV human glioblastoma xenograft - Control 27.1806990
GSM967854U87-EV human glioblastoma xenograft - Control 37.1257789
GSM967855U87-EV human glioblastoma xenograft - Control 47.4641790
GSM967856U87-EV human glioblastoma xenograft - Control 57.1998490
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0336590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0178390
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1582490
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2684791
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1237889
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0789889
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.336790
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2971690
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.10689